Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor progression in malignant lymphomas.

R A Warnke1

  • 1Department of Pathology, Stanford University School of Medicine, California 94305.

Bulletin Du Cancer
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Light-chain-restricted germinal centres in reactive lymphadenitis: report of eight cases.

Histopathology·2008
Same author

Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Histopathology·2002
Same author

Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.

Clinical lymphoma·2002
Same author

Ovarian non-Hodgkin's lymphoma: a clinicopathologic study of eight primary cases.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2001
Same author

Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2001
Same author

Angiocentric lymphomas (lymphomatous vasculitis).

Seminars in diagnostic pathology·2001
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
Same journal

[Robotics in oncological surgery].

Bulletin du cancer·2026
See all related articles

Low-grade lymphomas can transform into aggressive forms, often marked by diffuse infiltration and large cell proliferation. Researchers studied cell markers to understand factors associated with this lymphoma progression.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Low-grade lymphomas, originating from B or T cell lineages, frequently transform into more aggressive subtypes.
  • This progression is pathologically characterized by a shift to diffuse infiltration and proliferation of large lymphoid cells.
  • Similar transformations occur in small lymphocytic lymphomas and T-cell lymphomas like mycosis fungoides.

Purpose of the Study:

  • To investigate potential tumor cell or host cell features associated with lymphoma progression.
  • To correlate clinical findings with specific cell marker expressions in lymphoma subtypes.

Main Methods:

  • Application of various cell markers to different lymphoma subtypes.
  • Analysis of clinical correlations with tumor cell features including lineage, histocompatibility antigen expression, Lymphocyte Function-Associated Antigen 1 (LFA-1) expression, and proliferation markers.

Related Experiment Videos

  • Evaluation of the clinical significance of CD4+ cell counts in small B-cell lineage lymphomas.

    • Main Results:

    • Tumor cell and host cell features were analyzed for their association with lymphoma progression.
    • Clinical correlations were established between tumor cell characteristics and disease progression.
    • The role of CD4+ cells in small B-cell lymphomas was specifically examined.

    Conclusions:

    • Certain cell markers and features are associated with the progression of low-grade lymphomas.
    • Understanding these features can aid in predicting or managing lymphoma transformation.
    • Further research into cell markers may reveal new therapeutic targets for aggressive lymphomas.